Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is cu…
Biotechnology
US, South San Francisco [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peers Performance
Similar Stocks · Adjusted CloseA quick analysis that compared Tempest Therapeutics, Inc. (TPST) to it's peer group.
Peer Group
RVMD AKTX CGEM LIFE RZLT IKNA ZNTL RNXT SCPS LYEL ZIVO OLMA SANA PCSA INDP GLUE ANEB FBRX CBIO CMRA THRX
Compare Together
Loading...